Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:54:70-78.
doi: 10.1016/j.breast.2020.08.017. Epub 2020 Sep 7.

Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis

Jiaqiang Zhang  1 , Chang-Yun Lu  2 , Chien-Hsin Chen  3 , Ho-Min Chen  4 , Szu-Yuan Wu  5
Affiliations

Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis

Jiaqiang Zhang et al. Breast. 2020 Dec.

Abstract

Purpose: To use pathologic indicators to determine which patients benefit from postmastectomy radiation therapy (PMRT) for breast cancer after neoadjuvant chemotherapy (NACT) and total mastectomy (TM).

Patients and methods: We enrolled 4236 patients with breast invasive ductal carcinoma who received NACT followed by TM. Cox regression analysis was used to calculate hazard ratios (HRs) and confidence intervals; independent predictors were controlled for or stratified in the analysis.

Results: After multivariate Cox regression analyses, the adjusted HRs derived for PMRT for all-cause mortality were 0.65 (0.52-0.81, P < 0.0001) and 0.58 (0.47-0.71, P < 0.0001) in postchemotherapy pathologic tumor stages T2-4 (ypT3-4) and postchemotherapy pathologic nodal stages N2-3 (ypN2-3), respectively. Moreover, adjusted HRs derived for PMRT with all-cause mortality were 0.51 (0.38-0.69, P < 0.0001), 0.60 (0.40-0.88, P = 0.0096), and 0.64 (0.48-0.86, P = 0.0024) in pathological stages IIIA, IIIB, and IIIC, respectively. Additionally, the PMRT group showed significant locoregional control irrespective of the pathologic response, even ypT0, ypN0, or pathological complete response (pCR), compared with the No-PMRT group. The multivariate analysis showed no statistical differences between the PMRT and No-PMRT groups for distant metastasis-free survival in any pathologic response of ypT0-4, ypN0-3, and pathologic American Joint Committee on Cancer stages pCR to IIIC.

Conclusion: For patients with breast cancer ypT3-4, ypN2-3, or pathologic stages IIIA-IIIC receiving NACT and TM, benefit from PMRT if it is associated with OS benefits, regardless of the clinical stage of the disease. Compared with No-PMRT, PMRT improved locoregional recurrence-free survival, even pCR, in patients with breast cancer receiving NACT and TM.

Keywords: Breast cancer; Neoadjuvant chemotherapy; Pathologic response; Postmastectomy radiation therapy; Survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors have no potential conflicts of interest to declare. The datasets supporting the study conclusions are included within the manuscript.

Figures

Fig. 1
Fig. 1
Impact of PMRT on overall survival in multivariate Cox regression analysis for patients who received total mastectomy with or without PMRT. Adjusted hazard ratio: All variables presented in Table 2 were used in the multivariate analysis. HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; T, tumor; N, nodal.
Fig. 2
Fig. 2
Impact of PMRT on locoregional recurrence-free survival in multivariate Cox regression analysis for patients who received total mastectomy with or without PMRT. Adjusted hazard ratio: All variables presented in Table 2 were used in the multivariate analysis. HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; T, tumor; N, nodal.
See this image and copyright information in PMC

References

    1. Teshome M., Hunt K.K. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin. 2014;23:505–523. - PMC - PubMed
    1. Guarneri V., Dieci M.V., Barbieri E., Piacentini F., Omarini C., Ficarra G. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013;24:2990–2994. - PubMed
    1. Thompson A.M., Moulder-Thompson S.L. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(Suppl 10):x231–x236. - PMC - PubMed
    1. Cance W.G., Carey L.A., Calvo B.F., Sartor C., Sawyer L., Moore D.T. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236:295–302. discussion -3. - PMC - PubMed
    1. Chen J.H., Feig B.A., Hsiang D.J., Butler J.A., Mehta R.S., Bahri S. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009;249:448–454. - PMC - PubMed

MeSH terms